Critical Survey: WaferGen Bio-systems (WGBS) versus Oxford Immunotec Global PLC (OXFD)
WaferGen Bio-systems (NASDAQ: WGBS) and Oxford Immunotec Global PLC (NASDAQ:OXFD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitabiliy, earnings, dividends and risk.
Insider & Institutional Ownership
49.8% of WaferGen Bio-systems shares are owned by institutional investors. Comparatively, 87.5% of Oxford Immunotec Global PLC shares are owned by institutional investors. 5.8% of WaferGen Bio-systems shares are owned by insiders. Comparatively, 7.6% of Oxford Immunotec Global PLC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares WaferGen Bio-systems and Oxford Immunotec Global PLC’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Oxford Immunotec Global PLC||$90.47 million||4.29||-$22.95 million||($1.05)||-16.11|
WaferGen Bio-systems has higher revenue, but lower earnings than Oxford Immunotec Global PLC. Oxford Immunotec Global PLC is trading at a lower price-to-earnings ratio than WaferGen Bio-systems, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
WaferGen Bio-systems has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Oxford Immunotec Global PLC has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500.
This table compares WaferGen Bio-systems and Oxford Immunotec Global PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oxford Immunotec Global PLC||-25.83%||-31.48%||-22.01%|
This is a breakdown of recent recommendations and price targets for WaferGen Bio-systems and Oxford Immunotec Global PLC, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oxford Immunotec Global PLC||0||0||1||0||3.00|
Oxford Immunotec Global PLC has a consensus target price of $19.00, indicating a potential upside of 12.29%. Given Oxford Immunotec Global PLC’s higher possible upside, analysts plainly believe Oxford Immunotec Global PLC is more favorable than WaferGen Bio-systems.
Oxford Immunotec Global PLC beats WaferGen Bio-systems on 9 of the 10 factors compared between the two stocks.
About WaferGen Bio-systems
WaferGen Bio-systems, Inc. (WaferGen) is engaged in the development, manufacture and sale of genomic technology solutions for single-cell analysis (SCA) and clinical research. The Company focuses on marketing an open format genetic analysis system, the WaferGen SmartChip System. The Company’s ICELL8 Single-Cell System is a platform that can isolate a range of single cells and process specific cells for analysis, including Next Generation Sequencing (NGS). ICELL8 is based upon the Company’s SmartChip platform, which is also used for profiling and validating molecular biomarkers. The Company’s SmartChip is a micro-fabricated chip comprising a range of massively-parallel micro wells that are physically separated from each other. It offers SmartChip System Capabilities, SmartChip Single-Cell Isolation System, SmartChip Target Enrichment (TE) System and Apollo 324 Library Preparation.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Receive News & Ratings for WaferGen Bio-systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WaferGen Bio-systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.